Back to top


  /    /  LACOG 0519 – PEACE III

A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

Type of Study: Clinical Trial

Sponsor / Support: EORTC, Bayer, Astellas Pharma

Primary Objectives: The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone

Design: This is a randomized phase III open label trial. 

Sample Size: 560 patients

Principal Investigator: Andrey Soares (Steering Committee – LACOG)

Countries LATAM: Brazil Identifier:NCT02194842

The study is open to patients participation in the following research sites:

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

BP - A Beneficência Portuguesa de São Paulo / São Paulo / SP / Brazil

Hospital São Camilo / São Paulo / SP / Brazil

Hospital Moinhos de Vento / Porto Alegre / RS / Brazil

Clion / Salvador / BA / Brazil

Oncocentro Ceará / Fortaleza / CE / Brazil

Hospital Erasto Gaertner / Curitiba / PR / Brazil

CEPON - Centro de Pesquisas Oncológicas / Florianópolis / SC / Brazil